-
Miranda Lambert Leads North Texans with Seven Grammy Nominations for 2027
-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
NexCore and MetLife Investment Management Launch $1.3 Billion Senior Living Co-Investment Venture
-
Galway Metals Intersects 1.8 g/t Gold Over 25.0 Metres and 0.7 g/t Gold Over 66.0 Metres at Clarence Stream
-
RuffleButts + RuggedButts Featured in Hasbro's 2026 Holiday Gift Guide
-
KIDZ AI Announces Strategic Collaboration with Synestria to Optimize AI Infrastructure Performance
-
Brightline Interactive and TruWeather Solutions Sign MOU to Bring Weather Data into SpatialCore Physical AI Platform
-
Avino Announces Key Technical Appointment
-
HippoFi Achieves OTCID Market Designation, Opening a New Chapter of Commercial Growth
-
Gabriel Resources Provides Corporate and Financing Update
-
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
-
Pivotree Announces Third Quarter 2026 Results
-
Ur-Energy Commences Baseline Study Fieldwork; Nears Completion of Technical Report at Lost Soldier Uranium Project, Wyoming
-
ImageWorks Display Advances Whole-Store Solutions with a Re-Imagined Planniq Strong and Planniq Chill
-
Razavi Law Group Partners with Chapman University to Prepare the Next Generation of Attorneys
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
How to Turn Your Garage into Usable Living Space
-
Glidewell Opens Applications for 2027 Guiding Leaders Cohorts in California and North Carolina
-
The Next Healthcare Story Worth Telling May Be About Someone You Know
-
NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
-
Atlas Signal Initiates Coverage of High Roller Technologies: ROLR(TM) Prediction-Markets Platform Goes Live on iPhone for U.S. Customers
-
Join Nord Precious Metals' Live Investor Webinar: Advancing Silver Production and High-Grade Exploration in Ontario
-
Executing Our Plan, Increasing Equity and Reducing Liabilities in Order to Build Long-Term Value
-
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
-
Nexscient Reports Third Quarter 2026 Results; Revenue Rises Sequentially as Gross Margin Expands to Over 40%
-
Viking Global Technologies Announces Expansion of Grid Protection Technology Pilot with Another Major U.S. Electric Utility
-
TRNR Reports Record Q3 2026 Results, Driven by 66% Revenue Growth; M&A Pipeline Grows Significantly
-
Pinnacle Food Group Limited Achieves Laboratory-Scale Astaxanthin Extraction in Haematococcus pluvialis Program
-
FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at Osaka Major
-
Waste Energy to Host Shareholder Update Today at 4:30 PM EST; Management to Discuss WE #1 Commissioning, Revenue Opportunities and Growth Strategy
-
Klique Joins Lenovo AI Innovators, Bringing Its Enterprise AI Control Plane to Lenovo Hybrid AI Factory
-
Miami Allstars FC have Applied to Compete in the Women's Premier Soccer League, with the Club Targeting a 2027 or 2028 Debut in North Miami, Florida
-
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
-
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital
-
Tectonic Metals Completes Record Drill Program at Flat, Advances Five Pillars of Growth Toward Major 2027 Milestones
-
BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
Onco-Innovations Advances Progress Towards First-in-Human Trial with Avance Clinical Start-Up Agreement
VANCOUVER, BC / ACCESS Newswire / August 4, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce it has entered into a Start-Up Agreement with Avance Clinical Pty Ltd ("Avance"), a leading contract research organization, to initiate key regulatory and clinical documentation, such as the scientific summaries and trial plans required to eventually apply for approvals for human testing, for the Company's lead candidate, the exclusively licensed Polynucleotide Kinase Phosphatase (PNKP) inhibitor (the "Technology"), a first-in-class, polymer-encapsulated therapy. The work is expected to lay the groundwork for regulatory clearance and clinical trial readiness.
Under the agreement, Avance will provide expert clinical and regulatory support to Onco as the Company pursues trials targeting advanced-stage cancers with PTEN1 or SHP-12 deficiency. Deliverables include the development of an Investigator's Brochure summarizing the drug's preclinical performance, the authorship of a detailed clinical trial protocol, and independent medical and statistical review related to a Phase I clinical study. These documents are essential prerequisites for regulatory agencies to evaluate the safety and scientific merit of an investigational therapy.
Additionally, Avance will perform a nonclinical gap analysis, reviewing existing data to identify any remaining preclinical work required for a future Investigational New Drug (IND) application. The agreement also covers the planning and preparation of a pre-IND meeting with the with the U.S. Food and Drug Administration (FDA), a critical regulatory milestone aimed at aligning Onco's trial design with agency expectations and reducing development risk.
"This collaboration with Avance is another example of our progress as we continue to move towards discovery to clinical development. It's about turning promising science into a real clinical opportunity for patients. Their regulatory and operational expertise will be essential in shaping a trial that is not only scientifically sound but also built for execution. We're excited to enter this collaboration with Avance," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Avance Clinical
Avance Clinical is a full-service Contract Research Organization (CRO) with clinical operations spanning Australia, New Zealand, Asia, North America, and Europe.3 The company is recognized for delivering high-quality clinical trials for international biotechs, with deep experience across oncology, rare diseases, CNS, cell and gene therapies, and infectious diseases.4 In the past five years, Avance has successfully completed over 60 trials in rare and orphan disease populations and more than 67 oncology studies globally, highlighting their strong specialty track record.5
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the benefits expected to be realized under the agreement with Nucro-Technics, and the Company's ability to move forward with its plans for regulatory approvals and the conduct of human and other further testing of its Technologies, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
1 PTEN is a tumor suppressor gene that helps prevent uncontrolled cell growth by regulating signals that control cell division and survival. Mutations or loss of PTEN function can disrupt this balance and lead to tumor formation. See PTEN gene - MedlinePlus Genetics: https://medlineplus.gov/genetics/gene/pten
2 SHP-1 is a protein that helps control cell signaling, acting as a "brake" on pathways that promote cell growth and survival. When SHP-1 is missing or inactive, these signals can become overactive, contributing to cancer development. See SHP-1 - National Center for Biotechnology Information (NCBI): https://www.ncbi.nlm.nih.gov/gene/5777
5 https://www.avancecro.com/therapeutic-areas/rare-disease-orphan-drug
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
A.O.Scott--AT